Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study
Séverine Vermeire(KU Leuven), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), Julien Santo(Abivax (France)), Parambir S. Dulai(University of California San Diego), Didier Scherrer(Abivax (France)), Britta Siegmund(Charité - Universitätsmedizin Berlin), Paul Gineste(Abivax (France)), Tadakazu Hisamatsu(Kyorin University), Josianne Nitcheu(Abivax (France)), Herbert Tilg(Innsbruck Medical University), Silvio Danese(Università Cattolica del Sacro Cuore), Christopher J. Rabbat(Abivax (France)), Aurelien Flatres(Abivax (France)), Laurent Peyrin-Biroulet(Inserm), Marla C. Dubinsky(New Leaders)
Cited by 10
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci
|Nature Genetics|2010|2.6k
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis
|Hepatology|2017|1.9k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k